# Skin & Aesthetics Research Peptides — Lumira Peptides > Lumira Peptides is a reference desk for Skin & Aesthetics research peptides — the GLOW blend and GHK-Cu — summarized from peer-reviewed literature. A digest, not a vendor or clinic. A calm reading desk for the published literature on copper-peptide and multi-peptide research in skin remodeling, wound repair, and hair biology — what the studies actually tested, in which species, and how strong the evidence really is. ## The short version Lumira Peptides is a reading desk, not a store. It collects what the published research literature actually says about two subjects that keep appearing in skin-science conversations: the GLOW peptide blend and its primary constituent, GHK-Cu (glycyl-L-histidyl-L-lysine copper complex). A *peptide* is just a short chain of amino acids — the same building blocks proteins are made of, only far smaller. These particular peptides have been studied because they appear to engage parts of the skin's repair and remodeling machinery: stimulating collagen and elastin synthesis, helping cells migrate into wounds, and supporting the formation of new blood vessels. This desk does one job: it tells you, in plain language and with citations, what each peptide was tested on, in which species (often rats, sometimes human cell cultures or small clinical trials), and how far that evidence actually reaches. Most of it does not extend neatly to everyday human use. None of what is described here is an approved medicine in this form. We do not sell anything, we do not give medical advice, and we never list a human dose. ## What this desk covers Two research subjects, approached from different levels of organization: - [**GLOW (research blend)**](/glow) is the lead — a co-formulated combination of three distinct peptides (GHK-Cu, BPC-157, and TB-500) that circulates in research and clinic-adjacent communities under the name "GLOW." Each constituent has its own published science, but the blend itself as a combined preparation has never been evaluated in a controlled clinical trial. This desk treats it as what it is: a mechanistic rationale built on individual-component evidence, not on blend-level proof. - [**GHK-Cu**](/ghk-cu) is the copper-carrying tripeptide that anchors the blend's skin rationale. Of the two subjects here, it has the most human evidence — though that evidence is mostly topical (creams and serums on the skin surface), with a built-in limitation: the peptide does not cross intact skin well on its own [8]. The frame connecting them is *luminance, radiance, and the science of skin repair* — the biological pathways the literature says are involved, presented honestly and with full acknowledgment of where animal data ends and human data begins. ## What are research peptides? The proteins in your body — collagen in the dermis, an enzyme in your gut, a signaling hormone — are long chains of amino acids folded into specific shapes. A *peptide* is a much shorter chain of the same amino acids, sometimes only three or four links. Because of their size and specificity, peptides can act like keys fitting particular cell-surface locks (receptors), switching processes on or off without the complexity of a full protein. A *research peptide* is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, and occasionally in early human pilot studies — but has **not** been approved by a regulator as a medicine for the use being discussed. When this desk reports a finding, it reports it the way the study did — for example, *in dermal fibroblast cultures* or *in Wistar rats* — never as a recommendation for people. The GHK tripeptide sequence occurs naturally inside type I collagen and in human plasma, which is the kind of biological precedent that gives researchers a starting rationale; it does not make GHK-Cu an approved drug, and it does not validate any particular human protocol. ## How these two fit into skin-biology research The GLOW blend and GHK-Cu approach skin and tissue repair from complementary directions. GHK-Cu operates at the dermal matrix level — signaling fibroblasts to build collagen, elastin, and glycosaminoglycans and rebalancing the enzymes that break that matrix down [4][5]. BPC-157, one of the other two GLOW constituents, contributes pro-angiogenic signaling through the VEGFR2 pathway — encouraging new blood-vessel growth that can support tissue oxygenation and repair [3]. TB-500, the third constituent, is the actin-binding fragment of thymosin beta-4, associated with cell migration and reduced scarring in animal wound models [7]. Together the combination thesis is a convergent-coverage argument: a matrix-building signal (GHK-Cu), a vascular/cytoprotective signal (BPC-157), and a cell-mobility/anti-scarring signal (TB-500) — though no study has tested all three together in humans [1]. Use the [compare page](/compare) to see them side by side, or read each compound page for the full literature summary. The frame that runs across both is *the biology of luminance and radiance* — what the research literature says actually happens at the cellular level when skin remodels, how the evidence for these peptides maps onto those processes, and where, precisely, that evidence is thin. --- Every claim on this desk is sourced to the peer-reviewed literature and labeled by the model in which it was observed — a literature digest where curiosity and rigor hold each other accountable.